Eating Disorders & GLP-1 RAs

About this resource

Glucagon-like peptide-1receptor agonists (GLP-1 RAs), such as semaglutide (Ozempic), are medications originally developed to treat type 2 diabetes. LP-1 RAs are now being used as an approved or off-label treatment for weight loss.

here is limited research available to help researchers, clinicians, and patients/consumers to understand the relationships between GLP-1 RAs and eating disorders (9). However, it is thought that GLP-1 RAs may negatively impact eating disorder symptomology and treatment in a number of ways.

This factsheet provides information for clinicians, researchers, and patients/consumers to understand more about the link between GLP-1 RAs and eating disorders, including risks, physical impacts, psychological impacts, and practice recommendations.

PDF Available ?Yes
Year2025

See also

Issue 60 I Eating Disorders in Aged Care: What does this look like?

NEDC e-Bulletin Editor’s Note Welcome to the 60th edition of the NEDC e-Bulletin.

Read more

7 Tips for Improving Your Body Image

Click here to download full size

Read more

Issue 61 I Culture: How it Defines Illness and Shapes Eating Disorder Management

NEDC e-Bulletin In our weight-conscious society, we sometimes forget that the whole world doesn't see the body the way we do (Becker, 1995).

Read more

Stepped System of Care - Filipino

Pinagsama ng National Eating Distorders Collaboration (NEDC) ang dalawang dekada ng sektor at consensus ng karanasan at pag-unlad ng serbisyo upang maging modelo ng yugto-yugtong sistema ng pangangalaga para sa mga sakit sa gawi sa pagkain (eating disorders) (Bilang 1).

Read more